Fluorescent Protein Targets for CE-LIF Drug Screening

用于 CE-LIF 药物筛选的荧光蛋白靶标

• 批准号: 6443482
• 负责人: JERZY OLEJNIK
• 金额: $ 10万
• 依托单位: AMBERGEN, INC
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-01 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6443482
• 关键词: biomarker; capillary electrophoresis; chemical cleavage; chemical conjugate; drug interactions; drug screening /evaluation; fluorescent dye /probe; technology /technique development

DESCRIPTION (provided by applicant): More rapid and economical methods of drug +____________________________________ screening are sought by the pharmaceutical industry due to the dramatic projected increase in the number of "druggable" targets. This project aims to develop such a method based on the use of novel tRNA-based fluorescent labeling of the N-terminus of proteins combined with affinity capillary electrophoresis (ACE). AmberGen will evaluate a series of monofunctional and bifunctional detection/affinity tags, which will be specifically incorporated at the N-terminus of proteins during their cell-free expression using specially prepared tRNA conjugates. Because of the ability to uniformly fluorescence label target proteins while preserving their activity, potential drug interactions can be screened using ACE combined with light induced fluorescence detection (LIF). In this approach, small alterations in mobility can be detected using low volumes of reagents. Photocleavable affinity tags provide a means to rapidly isolate expressed proteins from the cell-free lysate. In addition, a series of "chemically addressable" moieties will be incorporated at the N-terminus of proteins for post-translational conjugation to molecules that cannot be accommodated by the native protein initiation system. In Phase II, an ACE-LIF drug screening technology based on cell-free N-terminal labeling will be optimized. Aclara Biosciences will assist in the transfer of this technology to microfluidic devices. PROPOSED COMMERCIAL APPLICATION: The development of cell-free protein labeling systems for drug screening based on ACE-LIF will result in commercial products including reagents and hardware for drug screening as well as an integrated system which will be marketed to the pharmaceutical industry.

说明（由申请人提供）：更快速、更经济的给药方法